Sickle cell disease is associated with significant morbi-mortality hence the interest in an early and targeted care. At present, there is no plasmatic marker able to identify infants at higher risk of developping severe complications later in life. However, recent studies have demonstrated a correlation between certain complications of the disease and biomarkers of the endothelial dysfunction characterizing it. Investigators prospectively followed a cohort of children diagnosed with SCD through the universal neonatal screening using inflammatory and haemostatic plasmatic markers to study their annual evolution. Investigators then will evaluate potential associations between these biological markers and the occurrence of SCD related complications. A secondary objective of this study is to evaluate the repercussions of therapeutic intervention on these markers. .
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
41
Blood sampling at the age of 6 and 12 months, 2-3-4 years
Blood sampling before any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
CHU Saint Pierre
Brussels, Belgium
Hôpital Universitaire Des Enfants Reine Fabiola
Brussels, Belgium
HIS - Site Etterbeek-Ixelles
Brussels, Belgium
Plasmatic levels of IL-6 at 12 months of age
Measurement of plasmatic levels of IL-6 (fg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of IL-6 at 6 months of age
Measurement of plasmatic levels of IL-6 (fg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of IL-6 at 2 years of age
Measurement of plasmatic levels of IL-6 (fg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of IL-6 at 3 years of age
Measurement of plasmatic levels of IL-6 (fg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of IL-6 at 4 years of age
Measurement of plasmatic levels of IL-6 (fg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of IL-6 before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of IL-6 (fg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic levels of IL-1ß at 6 months of age
Measurement of plasmatic levels of IL-1ß (fg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of IL-1ß at 12 months of age
Measurement of plasmatic levels of IL-1ß (fg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of IL-1ß at 2 years of age
Measurement of plasmatic levels of IL-1ß (fg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of IL-1ß at 3 years of age
Measurement of plasmatic levels of IL-1ß (fg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of IL-1ß at 4 years of age
Measurement of plasmatic levels of IL-1ß (fg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of IL-1ß before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of IL-1ß (fg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic levels of IL-8 at 6 months of age
Measurement of plasmatic levels of IL-8 (fg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of IL-8 at 12 months of age
Measurement of plasmatic levels of IL-8 (fg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of IL-8 at 2 years of age
Measurement of plasmatic levels of IL-8 (fg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of IL-8 at 3 years of age
Measurement of plasmatic levels of IL-8 (fg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of IL-8 at 4 years of age
Measurement of plasmatic levels of IL-8 (fg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of IL-8 before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of IL-8 (fg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic levels of IL-10 at 6 months of age
Measurement of plasmatic levels of IL-10 (fg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of IL-10 at 12 months of age
Measurement of plasmatic levels of IL-10 (fg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of IL-10 at 2 years of age
Measurement of plasmatic levels of IL-10 (fg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of IL-10 at 3 years of age
Measurement of plasmatic levels of IL-10 (fg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of IL-10 at 4 years of age
Measurement of plasmatic levels of IL-10 (fg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of IL-10 before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of IL-10 (fg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic levels of IL-12 at 6 months of age
Measurement of plasmatic levels of IL-12 (fg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of IL-12 at 12 months of age
Measurement of plasmatic levels of IL-12 (fg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of IL-12 at 2 years of age
Measurement of plasmatic levels of IL-12 (fg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of IL-12 at 3 years of age
Measurement of plasmatic levels of IL-12 (fg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of IL-12 at 4 years of age
Measurement of plasmatic levels of IL-12 (fg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of IL-12 before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of IL-12 (fg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic levels of TNF alpha at 6 months of age
Measurement of plasmatic levels of TNF alpha (fg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of TNF alpha at 12 months of age
Measurement of plasmatic levels of TNF alpha (fg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of TNF alpha at 2 years of age
Measurement of plasmatic levels of TNF alpha (fg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of TNF alpha at 3 years of age
Measurement of plasmatic levels of TNF alpha (fg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of TNF alpha at 4 years of age
Measurement of plasmatic levels of TNF alpha (fg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of TNF alpha before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of TNF alpha (fg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic levels of ICAM-1 at 6 months of age
Measurement of plasmatic levels of ICAM-1 (pg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of ICAM-1 at 12 months of age
Measurement of plasmatic levels of ICAM-1 (pg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of ICAM-1 at 2 years of age
Measurement of plasmatic levels of ICAM-1 (pg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of ICAM-1 at 3 years of age
Measurement of plasmatic levels of ICAM-1 (pg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of ICAM-1 at 4 years of age
Measurement of plasmatic levels of ICAM-1 (pg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of ICAM-1 before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of ICAM-1 (pg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic levels of VCAM-1 at 6 months of age
Measurement of plasmatic levels of VCAM-1 (pg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of VCAM-1 at 12 months of age
Measurement of plasmatic levels of VCAM-1 (pg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of VCAM-1 at 2 years of age
Measurement of plasmatic levels of VCAM-1 (pg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of VCAM-1 at 3 years of age
Measurement of plasmatic levels of VCAM-1 (pg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of VCAM-1 at 4 years of age
Measurement of plasmatic levels of VCAM-1 (pg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of VCAM-1 before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of VCAM-1 (pg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic VCAM-1 levels after in vitro stimulation with LPS
Measurement of plasmatic levels of VCAM-1 (pg/mL) by flow cytometric assay after in vitro stimulation with LPS
Time frame: Plasmatic level of VCAM-1 after in vitro stimulation with LPS
Plasmatic levels of E-selectine at 6 months of age
Measurement of plasmatic levels of E-selectine (pg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of E-selectine at 12 months of age
Measurement of plasmatic levels of E-selectine (pg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of E-selectine at 2 years of age
Measurement of plasmatic levels of E-selectine (pg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of E-selectine at 3 years of age
Measurement of plasmatic levels of E-selectine (pg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of E-selectine at 4 years of age
Measurement of plasmatic levels of E-selectine (pg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of E-selectine before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of E-selectine (pg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic levels of P-selectine at 6 months of age
Measurement of plasmatic levels of P-selectine (pg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of P-selectine at 12 months of age
Measurement of plasmatic levels of P-selectine (pg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of P-selectine at 2 years of age
Measurement of plasmatic levels of P-selectine (pg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of P-selectine at 3 years of age
Measurement of plasmatic levels of P-selectine (pg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of P-selectine at 4 years of age
Measurement of plasmatic levels of P-selectine (pg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of P-selectine before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of P-selectine (pg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Plasmatic levels of Vascular Endothelial Growth Factor (VEGF) at 6 months of age
Measurement of plasmatic levels of VEGF (pg/mL) by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of Vascular Endothelial Growth Factor (VEGF) at 12 months of age
Measurement of plasmatic levels of VEGF (pg/mL) by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of Vascular Endothelial Growth Factor (VEGF) at 2 years of age
Measurement of plasmatic levels of VEGF (pg/mL) by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of Vascular Endothelial Growth Factor (VEGF) at 3 years of age
Measurement of plasmatic levels of VEGF (pg/mL) by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of Vascular Endothelial Growth Factor (VEGF) at 4 years of age
Measurement of plasmatic levels of VEGF (pg/mL) by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of VEGF before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of VEGF (pg/mL) by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
Lag time parameter in thrombin generation assay at 6 months of age
Measurement of lag time (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 6 months of age
Lag time parameter in thrombin generation assay at 12 months of age
Measurement of lag time (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 12 months of age
Lag time parameter in thrombin generation assay at 2 years of age
Measurement of lag time (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 2 years of age
Lag time parameter in thrombin generation assay at 3 years of age
Measurement of lag time (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 3 years of age
Lag time parameter in thrombin generation assay at 4 years of age
Measurement of lag time (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 4 years of age
Lag time parameter in thrombin generation assay before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of lag time (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: Before the introduction of any new sickle cell disease treatment
Peak height parameter in thrombin generation assay at 6 months of age
Measurement of peak height (nM) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 6 months of age
Peak height parameter in thrombin generation assay at 12 months of age
Measurement of peak height (nM) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 12 months of age
Peak height parameter in thrombin generation assay at 2 years of age
Measurement of peak height (nM) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 2 years of age
Peak height parameter in thrombin generation assay at 3 years of age
Measurement of peak height (nM) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 3 years of age
Peak height parameter in thrombin generation assay at 4 years of age
Measurement of peak height (nM) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 4 years of age
Peak height parameter in thrombin generation assay before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of peak height (nM) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: Before the introduction of any new sickle cell disease treatment
Time to peak parameter in thrombin generation assay at 6 months of age
Measurement of time to peak (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method
Time frame: 6 months of age
Time to peak parameter in thrombin generation assay at 12 months of age
Measurement of time to peak (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method
Time frame: 12 months of age
Time to peak parameter in thrombin generation assay at 2 years of age
Measurement of time to peak (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method
Time frame: 2 years of age
Time to peak parameter in thrombin generation assay at 3 years of age
Measurement of time to peak (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method
Time frame: 3 years of age
Time to peak parameter in thrombin generation assay at 4 years of age
Measurement of time to peak (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method
Time frame: 4 years of age
Time to peak parameter in thrombin generation assay before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of time to peak (minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method
Time frame: Before the introduction of any new sickle cell disease treatment
Endogenous thrombin potential parameter in thrombin generation assay at 6 months of age
Measurement of endogenous thrombin potential (nM x minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 6 months of age
Endogenous thrombin potential parameter in thrombin generation assay at 12 months of age
Measurement of endogenous thrombin potential (nM x minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 12 months of age
Endogenous thrombin potential parameter in thrombin generation assay at 2 years of age
Measurement of endogenous thrombin potential (nM x minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 2 years of age
Endogenous thrombin potential parameter in thrombin generation assay at 3 years of age
Measurement of endogenous thrombin potential (nM x minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 3 years of age
Endogenous thrombin potential parameter in thrombin generation assay at 4 years of age
Measurement of endogenous thrombin potential (nM x minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: 4 years of age
Endogenous thrombin potential parameter in thrombin generation assay before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of endogenous thrombin potential (nM x minutes) parameter of thrombin generation in platelet poor plasma using the Calibrated Automated Thrombogram (CAT®) method.
Time frame: before the introduction of any new sickle cell disease treatment
Plasmatic levels of Factor VIII at 6 months of age
Measurement of plasmatic levels of Factor VIII by flow cytometric assay
Time frame: 6 months of age
Plasmatic levels of Factor VIII at 12 months of age
Measurement of plasmatic levels of Factor VIII by flow cytometric assay
Time frame: 12 months of age
Plasmatic levels of Factor VIII at 2 years of age
Measurement of plasmatic levels of Factor VIII by flow cytometric assay
Time frame: 2 years of age
Plasmatic levels of Factor VIII at 3 years of age
Measurement of plasmatic levels of Factor VIII by flow cytometric assay
Time frame: 3 years of age
Plasmatic levels of Factor VIII at 4 years of age
Measurement of plasmatic levels of Factor VIII by flow cytometric assay
Time frame: 4 years of age
Plasmatic levels of Factor VIII before the introduction of any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Measurement of plasmatic levels of Factor VIII by flow cytometric assay
Time frame: Before the introduction of any new sickle cell disease treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.